Insmed reported $765K in Interest Income for its fiscal quarter ending in September of 2024.





Interest Income Change Date
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Cytokinetics USD 11.02M 448K Mar/2026
DBV Technologies USD -0.32 0.02 Sep/2024
Gilead Sciences USD 95M 0 Mar/2026
Heron Therapeutics USD 433K 277K Dec/2021
Insmed USD 765K 55K Sep/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026